JP2014515041A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515041A5 JP2014515041A5 JP2014510942A JP2014510942A JP2014515041A5 JP 2014515041 A5 JP2014515041 A5 JP 2014515041A5 JP 2014510942 A JP2014510942 A JP 2014510942A JP 2014510942 A JP2014510942 A JP 2014510942A JP 2014515041 A5 JP2014515041 A5 JP 2014515041A5
- Authority
- JP
- Japan
- Prior art keywords
- oxo
- diaza
- bicyclo
- trans
- hydrazinocarbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 N ′-[(S) -pyrrolidine-2-carbonyl] -hydrazinocarbonyl Chemical group 0.000 claims 37
- 150000002148 esters Chemical class 0.000 claims 28
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 25
- 239000003242 anti bacterial agent Substances 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 19
- 229910052736 halogen Inorganic materials 0.000 claims 17
- 150000002367 halogens Chemical class 0.000 claims 17
- 125000001424 substituent group Chemical group 0.000 claims 17
- 208000035143 Bacterial infection Diseases 0.000 claims 16
- 208000022362 bacterial infectious disease Diseases 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 claims 11
- 229960005256 sulbactam Drugs 0.000 claims 11
- 241000894006 Bacteria Species 0.000 claims 8
- 229930186147 Cephalosporin Natural products 0.000 claims 8
- 108090000204 Dipeptidase 1 Proteins 0.000 claims 8
- 102000006635 beta-lactamase Human genes 0.000 claims 8
- 229940124587 cephalosporin Drugs 0.000 claims 8
- 150000001780 cephalosporins Chemical class 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 208000015181 infectious disease Diseases 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 229930182555 Penicillin Natural products 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims 5
- 229960003324 clavulanic acid Drugs 0.000 claims 5
- 159000000000 sodium salts Chemical class 0.000 claims 5
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 claims 5
- 229960003865 tazobactam Drugs 0.000 claims 5
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims 4
- 108010028921 Lipopeptides Proteins 0.000 claims 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 4
- 239000004098 Tetracycline Substances 0.000 claims 4
- 229940126575 aminoglycoside Drugs 0.000 claims 4
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims 4
- 229960003644 aztreonam Drugs 0.000 claims 4
- 239000003781 beta lactamase inhibitor Substances 0.000 claims 4
- 229940126813 beta-lactamase inhibitor Drugs 0.000 claims 4
- JSVCEVCSANKFDY-SFYZADRCSA-N carbacephem Chemical compound C1CC(C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)C)[C@H]21 JSVCEVCSANKFDY-SFYZADRCSA-N 0.000 claims 4
- 229960002100 cefepime Drugs 0.000 claims 4
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 claims 4
- 229960000484 ceftazidime Drugs 0.000 claims 4
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 claims 4
- UCKZMPLVLCKKMO-LHLIQPBNSA-N cephamycin Chemical compound S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](C)[C@]21OC UCKZMPLVLCKKMO-LHLIQPBNSA-N 0.000 claims 4
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 4
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 claims 4
- 229960001907 nitrofurazone Drugs 0.000 claims 4
- 229940049954 penicillin Drugs 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 4
- ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 claims 4
- 229960000885 rifabutin Drugs 0.000 claims 4
- 229940124530 sulfonamide Drugs 0.000 claims 4
- 150000003456 sulfonamides Chemical class 0.000 claims 4
- 229960002180 tetracycline Drugs 0.000 claims 4
- 229930101283 tetracycline Natural products 0.000 claims 4
- 235000019364 tetracycline Nutrition 0.000 claims 4
- 150000003522 tetracyclines Chemical class 0.000 claims 4
- 239000004599 antimicrobial Substances 0.000 claims 3
- 229940036735 ceftaroline Drugs 0.000 claims 3
- ZCCUWMICIWSJIX-NQJJCJBVSA-N ceftaroline fosamil Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OCC)C=2N=C(NP(O)(O)=O)SN=2)CC=1SC(SC=1)=NC=1C1=CC=[N+](C)C=C1 ZCCUWMICIWSJIX-NQJJCJBVSA-N 0.000 claims 3
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 claims 3
- QYQDKDWGWDOFFU-IUODEOHRSA-N Cefotiam Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 claims 2
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 claims 2
- KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 claims 2
- JWCSIUVGFCSJCK-CAVRMKNVSA-N Disodium Moxalactam Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CO[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C1=CC=C(O)C=C1 JWCSIUVGFCSJCK-CAVRMKNVSA-N 0.000 claims 2
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 229940041011 carbapenems Drugs 0.000 claims 2
- RRYMAQUWDLIUPV-BXKDBHETSA-N cefacetrile Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC#N)[C@@H]12 RRYMAQUWDLIUPV-BXKDBHETSA-N 0.000 claims 2
- 229960003972 cefacetrile Drugs 0.000 claims 2
- 229960005361 cefaclor Drugs 0.000 claims 2
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 claims 2
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 claims 2
- 229960003866 cefaloridine Drugs 0.000 claims 2
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 claims 2
- 229960000603 cefalotin Drugs 0.000 claims 2
- 229960003012 cefamandole Drugs 0.000 claims 2
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 claims 2
- 229960001139 cefazolin Drugs 0.000 claims 2
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims 2
- 229960001817 cefbuperazone Drugs 0.000 claims 2
- SMSRCGPDNDCXFR-CYWZMYCQSA-N cefbuperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H]([C@H](C)O)C(=O)N[C@]1(OC)C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 SMSRCGPDNDCXFR-CYWZMYCQSA-N 0.000 claims 2
- JUVHVMCKLDZLGN-TVNFHGJBSA-N cefclidin Chemical compound N([C@@H]1C(N2C(=C(C[N+]34CCC(CC3)(CC4)C(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=NSC(N)=N1 JUVHVMCKLDZLGN-TVNFHGJBSA-N 0.000 claims 2
- 229960003719 cefdinir Drugs 0.000 claims 2
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 claims 2
- 229960002142 cefditoren pivoxil Drugs 0.000 claims 2
- AFZFFLVORLEPPO-UVYJNCLZSA-N cefditoren pivoxil Chemical compound S([C@@H]1[C@@H](C(N1C=1C(=O)OCOC(=O)C(C)(C)C)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C AFZFFLVORLEPPO-UVYJNCLZSA-N 0.000 claims 2
- DASYMCLQENWCJG-XUKDPADISA-N cefetamet pivoxil Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(=O)OCOC(=O)C(C)(C)C)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DASYMCLQENWCJG-XUKDPADISA-N 0.000 claims 2
- 229950000726 cefetamet pivoxil Drugs 0.000 claims 2
- 229960002129 cefixime Drugs 0.000 claims 2
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 claims 2
- XAKKNLNAJBNLPC-MAYKBZFQSA-N cefluprenam Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)/C=C/C[N+](C)(CC)CC(N)=O)C([O-])=O)C(=O)C(=N/OCF)\C1=NSC(N)=N1 XAKKNLNAJBNLPC-MAYKBZFQSA-N 0.000 claims 2
- 229950001334 cefluprenam Drugs 0.000 claims 2
- 229960004261 cefotaxime Drugs 0.000 claims 2
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 claims 2
- 229960001242 cefotiam Drugs 0.000 claims 2
- 229960002682 cefoxitin Drugs 0.000 claims 2
- QDUIJCOKQCCXQY-WHJQOFBOSA-N cefozopran Chemical compound N([C@@H]1C(N2C(=C(CN3C4=CC=CN=[N+]4C=C3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=NSC(N)=N1 QDUIJCOKQCCXQY-WHJQOFBOSA-N 0.000 claims 2
- 229960002642 cefozopran Drugs 0.000 claims 2
- LNZMRLHZGOBKAN-KAWPREARSA-N cefpimizole Chemical compound N1=CNC(C(=O)N[C@@H](C(=O)N[C@@H]2C(N3C(=C(C[N+]=4C=CC(CCS(O)(=O)=O)=CC=4)CS[C@@H]32)C([O-])=O)=O)C=2C=CC=CC=2)=C1C(=O)O LNZMRLHZGOBKAN-KAWPREARSA-N 0.000 claims 2
- 229950004036 cefpimizole Drugs 0.000 claims 2
- 229960003202 cefsulodin Drugs 0.000 claims 2
- SYLKGLMBLAAGSC-QLVMHMETSA-N cefsulodin Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@@H](C=3C=CC=CC=3)S(O)(=O)=O)[C@H]2SC1 SYLKGLMBLAAGSC-QLVMHMETSA-N 0.000 claims 2
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 claims 2
- 229960001991 ceftizoxime Drugs 0.000 claims 2
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 claims 2
- 229960004755 ceftriaxone Drugs 0.000 claims 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims 2
- 229960001668 cefuroxime Drugs 0.000 claims 2
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims 2
- 229960002620 cefuroxime axetil Drugs 0.000 claims 2
- 229940106164 cephalexin Drugs 0.000 claims 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims 2
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims 2
- 229960000895 doripenem Drugs 0.000 claims 2
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims 2
- 229960002182 imipenem Drugs 0.000 claims 2
- 229960000433 latamoxef Drugs 0.000 claims 2
- 229960002260 meropenem Drugs 0.000 claims 2
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims 2
- 229940041009 monobactams Drugs 0.000 claims 2
- 150000002961 penems Chemical class 0.000 claims 2
- 150000002960 penicillins Chemical class 0.000 claims 2
- 229960002292 piperacillin Drugs 0.000 claims 2
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 claims 2
- 229940124586 β-lactam antibiotics Drugs 0.000 claims 2
- HYDTWJWCBMFIQL-GMTAPVOTSA-N 2-[[(2r,5r)-7-oxo-2-[[[(3r)-piperidine-3-carbonyl]amino]carbamoyl]-1,6-diazabicyclo[3.2.1]octan-6-yl]oxy]acetic acid Chemical compound O=C([C@@H]1N2C[C@@](CC1)(N(C2=O)OCC(O)=O)[H])NNC(=O)[C@@H]1CCCNC1 HYDTWJWCBMFIQL-GMTAPVOTSA-N 0.000 claims 1
- MBMIFCNAWJUXOY-HBNTYKKESA-N C1C[C@H](NC1)CCC(=O)NNC(=O)[C@H]2CC[C@@H]3CN2C(=O)N3OS(=O)(=O)O Chemical compound C1C[C@H](NC1)CCC(=O)NNC(=O)[C@H]2CC[C@@H]3CN2C(=O)N3OS(=O)(=O)O MBMIFCNAWJUXOY-HBNTYKKESA-N 0.000 claims 1
- NUSJTKGZIBQZGQ-SCLLHFNJSA-M CC(C)(C(NNC([C@@H](CC[C@H](C1)N2OS([O-])(=O)=O)N1C2=O)=O)=O)C#N.[Na+] Chemical compound CC(C)(C(NNC([C@@H](CC[C@H](C1)N2OS([O-])(=O)=O)N1C2=O)=O)=O)C#N.[Na+] NUSJTKGZIBQZGQ-SCLLHFNJSA-M 0.000 claims 1
- 229940123930 Lactamase inhibitor Drugs 0.000 claims 1
- UYLDIIWDUDIANL-RFZPGFLSSA-N [(2R,5R)-2-(hydrazinecarbonyl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound N(N)C(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O UYLDIIWDUDIANL-RFZPGFLSSA-N 0.000 claims 1
- XBQYSOJNZSCBNF-RNFRBKRXSA-N [(2R,5R)-2-[(3-aminopropanoylamino)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound NCCC(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O XBQYSOJNZSCBNF-RNFRBKRXSA-N 0.000 claims 1
- DKQYIDUFCOSIGB-HTQZYQBOSA-N [(2R,5R)-2-[(4-aminobutanoylamino)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound NCCCC(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O DKQYIDUFCOSIGB-HTQZYQBOSA-N 0.000 claims 1
- OGLYOHMUJKXRIO-RKDXNWHRSA-N [(2R,5R)-2-[(5-aminopentanoylamino)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound NCCCCC(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O OGLYOHMUJKXRIO-RKDXNWHRSA-N 0.000 claims 1
- XYTWGTZSUPIYFZ-HTQZYQBOSA-N [(2R,5R)-2-[(azetidine-3-carbonylamino)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound N1CC(C1)C(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O XYTWGTZSUPIYFZ-HTQZYQBOSA-N 0.000 claims 1
- APBHTOUFSZXYCV-PHDIDXHHSA-N [(2R,5R)-2-[[(2-aminoacetyl)amino]carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound NCC(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O APBHTOUFSZXYCV-PHDIDXHHSA-N 0.000 claims 1
- QEJZBLVKSRUUKM-DSYKOEDSSA-N [(2R,5R)-2-[[[(2S)-2-amino-3-hydroxypropanoyl]amino]carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound N[C@H](C(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O)CO QEJZBLVKSRUUKM-DSYKOEDSSA-N 0.000 claims 1
- HGDFYIWSKIRGEH-LURQLKTLSA-N [(2R,5R)-2-[[[(2S,4R)-4-hydroxypyrrolidine-2-carbonyl]amino]carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound O[C@@H]1C[C@H](NC1)C(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O HGDFYIWSKIRGEH-LURQLKTLSA-N 0.000 claims 1
- BSIPLMLCLGSFOX-DOLQZWNJSA-N [(2R,5R)-2-[[[(2S,4R)-4-methoxypyrrolidine-2-carbonyl]amino]carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound CO[C@@H]1C[C@H](NC1)C(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O BSIPLMLCLGSFOX-DOLQZWNJSA-N 0.000 claims 1
- UDWBQLXRVRBWLL-UYXSQOIJSA-N [(2R,5R)-2-[[[(2S,4S)-4-(diaminomethylideneamino)pyrrolidine-2-carbonyl]amino]carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound N(C(=N)N)[C@H]1C[C@H](NC1)C(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O UDWBQLXRVRBWLL-UYXSQOIJSA-N 0.000 claims 1
- CIIXHNAIHMNPNA-UYXSQOIJSA-N [(2R,5R)-2-[[[(2S,4S)-4-aminopyrrolidine-2-carbonyl]amino]carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound N[C@H]1C[C@H](NC1)C(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O CIIXHNAIHMNPNA-UYXSQOIJSA-N 0.000 claims 1
- HHIXMUSUBFKSRV-UYXSQOIJSA-N [(2R,5R)-2-[[[(2S,4S)-4-fluoropyrrolidine-2-carbonyl]amino]carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound F[C@H]1C[C@H](NC1)C(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O HHIXMUSUBFKSRV-UYXSQOIJSA-N 0.000 claims 1
- CJDXSFPMLHXKPP-PQDIPPBSSA-N [(2R,5R)-7-oxo-2-[(3-piperidin-2-ylpropanoylamino)carbamoyl]-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound N1C(CCCC1)CCC(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O CJDXSFPMLHXKPP-PQDIPPBSSA-N 0.000 claims 1
- KXTJXSAKJFXLEI-RCAUJQPQSA-N [(2R,5R)-7-oxo-2-[(piperidine-2-carbonylamino)carbamoyl]-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound N1C(CCCC1)C(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O KXTJXSAKJFXLEI-RCAUJQPQSA-N 0.000 claims 1
- GYXFEMGIRUYDEP-NXEZZACHSA-N [(2R,5R)-7-oxo-2-[(piperidine-4-carbonylamino)carbamoyl]-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound N1CCC(CC1)C(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O GYXFEMGIRUYDEP-NXEZZACHSA-N 0.000 claims 1
- GSHJUFCGOVFWMM-RKDXNWHRSA-N [(2R,5R)-7-oxo-2-[(pyrrolidine-1-carbonylamino)carbamoyl]-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound N1(CCCC1)C(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O GSHJUFCGOVFWMM-RKDXNWHRSA-N 0.000 claims 1
- NRZLXMVYLARNKK-NXEZZACHSA-N [(2R,5R)-7-oxo-2-[[(2-piperazin-1-ylacetyl)amino]carbamoyl]-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound N1CCN(CC1)CC(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O NRZLXMVYLARNKK-NXEZZACHSA-N 0.000 claims 1
- WXSCNWNDBSBAIG-NXEZZACHSA-N [(2R,5R)-7-oxo-2-[[(3-oxo-3-piperazin-1-ylpropanoyl)amino]carbamoyl]-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound O=C(CC(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O)N1CCNCC1 WXSCNWNDBSBAIG-NXEZZACHSA-N 0.000 claims 1
- KXTJXSAKJFXLEI-OPRDCNLKSA-N [(2R,5R)-7-oxo-2-[[[(2R)-piperidine-2-carbonyl]amino]carbamoyl]-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound N1[C@H](CCCC1)C(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O KXTJXSAKJFXLEI-OPRDCNLKSA-N 0.000 claims 1
- KXTJXSAKJFXLEI-KXUCPTDWSA-N [(2R,5R)-7-oxo-2-[[[(2S)-piperidine-2-carbonyl]amino]carbamoyl]-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound N1[C@@H](CCCC1)C(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O KXTJXSAKJFXLEI-KXUCPTDWSA-N 0.000 claims 1
- YCZPXRQPDCXTIO-OPRDCNLKSA-N [(2R,5R)-7-oxo-2-[[[(3R)-piperidine-3-carbonyl]amino]carbamoyl]-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound N1C[C@@H](CCC1)C(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O YCZPXRQPDCXTIO-OPRDCNLKSA-N 0.000 claims 1
- NAURQUDBIPQVFZ-IWSPIJDZSA-N [(2R,5R)-7-oxo-2-[[[(3R)-pyrrolidine-3-carbonyl]amino]carbamoyl]-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound N1C[C@@H](CC1)C(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O NAURQUDBIPQVFZ-IWSPIJDZSA-N 0.000 claims 1
- NAURQUDBIPQVFZ-DJLDLDEBSA-N [(2R,5R)-7-oxo-2-[[[(3S)-pyrrolidine-3-carbonyl]amino]carbamoyl]-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound N1C[C@H](CC1)C(=O)NNC(=O)[C@@H]1N2C(N([C@H](CC1)C2)OS(O)(=O)=O)=O NAURQUDBIPQVFZ-DJLDLDEBSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 150000001768 cations Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 229910052938 sodium sulfate Inorganic materials 0.000 claims 1
- 0 CNNC(C(CCC(C1)N2O*)N1C2=O)=O Chemical compound CNNC(C(CCC(C1)N2O*)N1C2=O)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2412/MUM/2011 | 2011-08-27 | ||
| IN2412MU2011 | 2011-08-27 | ||
| PCT/IB2012/054290 WO2013030733A1 (en) | 2011-08-27 | 2012-08-24 | 1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014515041A JP2014515041A (ja) | 2014-06-26 |
| JP2014515041A5 true JP2014515041A5 (enExample) | 2014-08-07 |
| JP5666743B2 JP5666743B2 (ja) | 2015-02-12 |
Family
ID=54289195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510942A Active JP5666743B2 (ja) | 2011-08-27 | 2012-08-24 | １，６−ジアザビシクロ［３，２，１］オクタン−７−オン誘導体および細菌感染の処置におけるそれらの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US8822450B2 (enExample) |
| EP (1) | EP2748165B1 (enExample) |
| JP (1) | JP5666743B2 (enExample) |
| KR (1) | KR101512738B1 (enExample) |
| CN (1) | CN103619843B (enExample) |
| AU (1) | AU2012303691B2 (enExample) |
| BR (1) | BR112013028813B1 (enExample) |
| CA (1) | CA2833241C (enExample) |
| DK (1) | DK2748165T3 (enExample) |
| ES (1) | ES2603198T3 (enExample) |
| HU (1) | HUE030311T2 (enExample) |
| MX (1) | MX348974B (enExample) |
| PL (1) | PL2748165T3 (enExample) |
| PT (1) | PT2748165T (enExample) |
| RU (2) | RU2636147C1 (enExample) |
| WO (1) | WO2013030733A1 (enExample) |
| ZA (1) | ZA201307631B (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6179588A (ja) * | 1984-09-28 | 1986-04-23 | 株式会社東芝 | 多関節ロボツト |
| AU2008316830B2 (en) | 2007-10-25 | 2016-03-17 | Cempra Pharmaceuticals, Inc. | Process for the preparation of macrolide antibacterial agents |
| CN107854477A (zh) | 2008-10-24 | 2018-03-30 | 森普拉制药公司 | 使用含三唑的大环内酯治疗抗性疾病的方法 |
| US9937194B1 (en) | 2009-06-12 | 2018-04-10 | Cempra Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory diseases |
| US9480679B2 (en) | 2009-09-10 | 2016-11-01 | Cempra Pharmaceuticals, Inc. | Methods for treating malaria, tuberculosis and MAC diseases |
| KR20130120458A (ko) | 2010-09-10 | 2013-11-04 | 셈프라 파마슈티컬스, 인크. | 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드 |
| US8772490B2 (en) | 2010-12-22 | 2014-07-08 | Meiji Seika Pharma Co., Ltd. | Optically active diazabicyclooctane derivatives and process for preparing the same |
| BR112013028813B1 (pt) * | 2011-08-27 | 2020-10-20 | Wockhardt Limited | derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem |
| US9505761B2 (en) | 2011-12-02 | 2016-11-29 | Fedora Pharmaceuticals Inc. | Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors |
| US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
| WO2013148891A1 (en) | 2012-03-27 | 2013-10-03 | Cempra Pharmaceuticals, Inc. | Parenteral formulations for administering macrolide antibiotics |
| AR090539A1 (es) | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | COMPUESTOS INHIBIDORES DE b LACTAMASA |
| HUE046893T2 (hu) | 2012-05-30 | 2020-04-28 | Meiji Seika Pharma Co Ltd | Új ß-laktamáz inhibitor és eljárás elõállítására |
| UA111925C2 (uk) * | 2012-12-11 | 2016-06-24 | Федора Фармасьютікалз Інк. | БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ |
| AU2014206087A1 (en) * | 2013-01-14 | 2015-05-28 | Wockhardt Limited | Compositions and methods for treating bacterial infections |
| BR112015021186A2 (pt) * | 2013-03-08 | 2017-07-18 | Wockhardt Ltd | processo para a preparação de (2s,5r)-7-oxo-6-sulfóxi-2-[((3r)-pirrolidina-3-carbonil)-hidrazino carbonil]-1,6-diaza-biciclo[3.2.1]octano |
| WO2014135931A1 (en) * | 2013-03-08 | 2014-09-12 | Wockhardt Limited | A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane |
| AU2013380574B2 (en) * | 2013-03-08 | 2016-07-07 | Wockhardt Limited | A process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2-[((3R)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane |
| KR101774132B1 (ko) * | 2013-03-08 | 2017-09-01 | 욱크하르트 리미티드 | (2s, 5r)-7-옥소-6-술포옥시-2-[((3r)-피페리딘-3-카보닐)-히드라지노 카보닐]-1,6-디아자-비사이클로[3.2.1]-옥탄의 제조 방법 |
| WO2014152326A1 (en) | 2013-03-14 | 2014-09-25 | Cempra Pharmaceuticals, Inc. | Methods for treating respiratory diseases and formulations therefor |
| US20140275000A1 (en) | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Ceftolozane pharmaceutical compositions |
| AU2014233240B2 (en) | 2013-03-15 | 2018-08-09 | Cempra Pharmaceuticals, Inc. | Convergent processes for preparing macrolide antibacterial agents |
| DK3050883T3 (da) | 2013-09-24 | 2020-05-25 | Meiji Seika Pharma Co Ltd | Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter |
| CN105612159A (zh) | 2013-10-08 | 2016-05-25 | 明治制果药业株式会社 | 二氮杂二环辛烷衍生物的结晶及其制备方法 |
| WO2015059643A1 (en) * | 2013-10-22 | 2015-04-30 | Wockhardt Limited | Pharmaceutical compositions comprising antibacterial agents |
| CN106163519A (zh) * | 2013-10-30 | 2016-11-23 | 沃克哈特有限公司 | 包含抗菌剂的药物组合物 |
| RU2705375C2 (ru) * | 2014-01-21 | 2019-11-07 | Вокхардт Лимитед | Фармацевтические композиции, содержащие антибактериальные агенты |
| WO2015110885A1 (en) * | 2014-01-21 | 2015-07-30 | Wockhardt Limited | A process for preparation of (2s,5r)-6-sulphooxy-7-oxo-2-[((3r)-piperidine-3-carbonyl)-hydrazinocarbonyl]-1,6-diaza-bicyclo[3.2.1] octane |
| CN106211771A (zh) * | 2014-01-21 | 2016-12-07 | 沃克哈特有限公司 | 含氮化合物及其作为抗菌剂的用途 |
| EP3125887A1 (en) * | 2014-03-29 | 2017-02-08 | Wockhardt Limited | Pharmaceutical compositions comprising cefepime or sulbactam |
| EP3131583A1 (en) * | 2014-04-18 | 2017-02-22 | The Wockhardt Limited | Pharmaceutical compositions comprising antibacterial agents |
| EP3185864A4 (en) * | 2014-08-05 | 2018-03-28 | Cempra Pharmaceuticals, Inc. | Powder oral suspension formulations of antibacterial agents |
| TWI690317B (zh) | 2014-11-17 | 2020-04-11 | 英商安特西醫療有限公司 | 用於治療抗藥性細菌感染之組合療法 |
| SG11201704576SA (en) | 2014-12-05 | 2017-07-28 | Meiji Seika Pharma Co Ltd | Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation |
| WO2016116788A1 (en) * | 2015-01-24 | 2016-07-28 | Wockhardt Limited | Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections |
| WO2016151543A1 (en) * | 2015-03-25 | 2016-09-29 | Wockhardt Limited | Pharmaceutical compositions comprising antibacterial agents |
| EP3075734A1 (en) * | 2015-03-31 | 2016-10-05 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| HK1244791A1 (zh) | 2015-03-31 | 2018-08-17 | 拜欧蒂姆公司 | 杂环化合物及它们在预防或治疗细菌感染中的应用 |
| WO2017002089A1 (en) | 2015-07-02 | 2017-01-05 | Wockhardt Limited | Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections |
| WO2017002083A1 (en) * | 2015-07-02 | 2017-01-05 | Wockhardt Limited | Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections |
| WO2017002086A1 (en) * | 2015-07-02 | 2017-01-05 | Wockhardt Limited | Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections |
| CA2984024A1 (en) * | 2015-09-16 | 2017-03-23 | Xuanzhu Pharma Co., Ltd. | .beta.-lactamase inhibitors and uses thereof |
| CN108137567A (zh) | 2015-10-02 | 2018-06-08 | 乐高化学生物科学股份有限公司 | 用于抑制β-内酰胺酶的组合物和方法 |
| US20190077802A1 (en) * | 2015-10-06 | 2019-03-14 | Wockhardt Limited | Difluoro-(2-substituted carbamoyl-1,6-diaza-bicyclo [3.2.1] oct-6-yloxy) acetic acid compounds and their use in treatment of bacterial infections |
| WO2017081615A1 (en) | 2015-11-09 | 2017-05-18 | Wockhardt Limited | 7-oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections |
| DE102016005299A1 (de) * | 2016-05-02 | 2017-11-02 | Eisele Pneumatics Gmbh & Co. Kg | Verfahren zum Herstellen eines gebogenen rohrförmigen Verbindungselementes |
| WO2017216764A1 (en) * | 2016-06-17 | 2017-12-21 | Wockhardt Limited | N-(alkanoyl)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carbonylhydrazide derivatives and their use as antibacterial agents |
| SG11201901658PA (en) * | 2016-09-16 | 2019-04-29 | Entasis Therapeutics Ltd | Beta-lactamase inhibitor compounds |
| WO2018141991A1 (en) * | 2017-02-06 | 2018-08-09 | Mutabilis | Novel heterocyclic compounds and their use in preventing or treating bacterial infections |
| EA037916B1 (ru) * | 2017-02-08 | 2021-06-07 | Энтасис Терапеутикс Лимитед | Соединения-ингибиторы бета-лактамаз |
| KR102354697B1 (ko) * | 2017-03-02 | 2022-01-21 | 욱크하르트 리미티드 | 항박테리아 화합물로서의 헤테로고리 유도체 |
| PT3630111T (pt) | 2017-05-08 | 2022-03-01 | Entasis Therapeutics Inc | Compostos e métodos de tratamento de infeções bacterianas |
| WO2018234962A1 (en) | 2017-06-20 | 2018-12-27 | Wockhardt Limited | Process for o-sulfonation of 1,6-diazabicyclo[3.2.1]octane compounds |
| US11180501B2 (en) | 2017-12-01 | 2021-11-23 | Qilu Pharmaceutical Co., Ltd. | Crystal form of β-lactamase inhibitor and preparation method therefor |
| WO2022047603A1 (en) * | 2020-09-01 | 2022-03-10 | Ningxia Academy Of Agriculture And Forestry Sciences | Beta-lactamase inhibitors and their preparation |
| GB202306826D0 (en) | 2023-05-09 | 2023-06-21 | Adjutec Pharma As | Therapy |
| GB202306833D0 (en) | 2023-05-09 | 2023-06-21 | Adjutec Pharma As | Therapy |
| CN117700415B (zh) * | 2024-02-06 | 2024-04-30 | 成都四面体药物研究有限公司 | 含脲双环化合物、其用途、其制备的药物、其联合用药物及其复方制剂 |
| WO2026104587A1 (en) | 2024-11-13 | 2026-05-21 | Adjutec Pharma As | Cyclic boronic acid esters useful as adjuvants in the treatment of bacterial infections |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0607164B1 (en) * | 1991-09-26 | 2002-05-02 | Pfizer Inc. | Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists |
| ATE177099T1 (de) * | 1993-12-29 | 1999-03-15 | Pfizer | Diazabicyclische neurokinin antagonisten |
| FR2812635B1 (fr) * | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
| FR2835186B1 (fr) * | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| JP5038509B2 (ja) * | 2008-01-18 | 2012-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | β−ラクタマーゼ阻害剤 |
| FR2937034B1 (fr) | 2008-10-10 | 2012-11-23 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens |
| FR2951171A1 (fr) * | 2009-10-09 | 2011-04-15 | Novexel | Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation |
| BR112013028813B1 (pt) * | 2011-08-27 | 2020-10-20 | Wockhardt Limited | derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem |
-
2012
- 2012-08-24 BR BR112013028813-2A patent/BR112013028813B1/pt active IP Right Grant
- 2012-08-24 US US14/111,592 patent/US8822450B2/en active Active
- 2012-08-24 MX MX2013013887A patent/MX348974B/es active IP Right Grant
- 2012-08-24 KR KR1020137034052A patent/KR101512738B1/ko active Active
- 2012-08-24 EP EP12772808.7A patent/EP2748165B1/en active Active
- 2012-08-24 ES ES12772808.7T patent/ES2603198T3/es active Active
- 2012-08-24 JP JP2014510942A patent/JP5666743B2/ja active Active
- 2012-08-24 RU RU2016106633A patent/RU2636147C1/ru active
- 2012-08-24 AU AU2012303691A patent/AU2012303691B2/en active Active
- 2012-08-24 RU RU2013155902/04A patent/RU2578370C2/ru active
- 2012-08-24 WO PCT/IB2012/054290 patent/WO2013030733A1/en not_active Ceased
- 2012-08-24 DK DK12772808.7T patent/DK2748165T3/en active
- 2012-08-24 PT PT127728087T patent/PT2748165T/pt unknown
- 2012-08-24 HU HUE12772808A patent/HUE030311T2/en unknown
- 2012-08-24 PL PL12772808T patent/PL2748165T3/pl unknown
- 2012-08-24 CN CN201280025141.8A patent/CN103619843B/zh active Active
- 2012-08-24 CA CA2833241A patent/CA2833241C/en active Active
-
2013
- 2013-10-14 ZA ZA2013/07631A patent/ZA201307631B/en unknown
-
2014
- 2014-06-03 US US14/294,364 patent/US8853197B1/en active Active
- 2014-08-06 US US14/452,652 patent/US8987297B2/en active Active
-
2015
- 2015-01-30 US US14/609,704 patent/US9132133B2/en active Active
- 2015-07-09 US US14/795,048 patent/US9381200B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013155902A (ru) | Производные 1,6-диазабицикло [3,2,1] октан-7-она и их применение при лечении бактериальных инфекционных болезней | |
| CA2842779C (en) | Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor | |
| RU2014109447A (ru) | Азотсодержащие соединения и их применение | |
| RU2014107902A (ru) | Производные 1,6-диазабицикло[3.2.1]октан-7-оно и их применение при лечении бактериальных инфекций | |
| RU2015110500A (ru) | Производные 1,6-диазабицикло[3.2.1]октан-7-она и их применение для лечения бактериальных инфекций | |
| JP2020502210A (ja) | 抗生物質耐性菌株による感染症向けのアミジン置換β−ラクタム化合物とβ−ラクタマーゼ阻害剤を用いた併用療法 | |
| AU2017203932B2 (en) | Compositions and methods for treating bacterial infections | |
| RU2017133660A (ru) | Новые гетероциклические соединения и их применение в профилактике или лечении бактериальных инфекций | |
| CN113194943A (zh) | 一种质量稳定的β内酰胺酶抑制剂组合物及其用途和方法 | |
| CA2889793C (en) | Antibacterial compositions | |
| WO2016116878A1 (en) | Antibacterial compositions of a beta-lactamase inhibitor with a cephalosporin | |
| RU2016113755A (ru) | Азотсодержащие соединения и их применение | |
| AU2016332964A1 (en) | Compositions and methods for inhibiting beta-lactamase | |
| RU2007145594A (ru) | Бициклические 6-алкилиден-пенемы в качестве ингибиторов бета-лактамазы класса-d | |
| BR112013030282B1 (pt) | Composições compreendendo cefepima e tazobactama | |
| EP0735871B1 (en) | Pharmaceutical compositions containing ceftriaxone and penems | |
| CA2468036C (en) | A method of treating bacterial infections using gemifloxacin or a salt thereof and a .beta.-lactam antibiotic | |
| US20040176349A1 (en) | Antibacterial composition |